Abstract
Yolk-shell mesoporous silica nanoparticles (YMSNs) were synthesized via a facile approach. The YMSNs displayed a relatively uniform size, good dispersity and hemocompatibility. The YMSNs were further used to construct a redox-responsive drug delivery system for targeted tumor therapy, by employing a special rotaxane nanovalve based on Pd as an end-capping agent, disulfide bonds as intermediate linkers and folic acid as a targeting motif. Various characterizations proved that the system had been successfully constructed. A series of biological assays demonstrated that the fabricated YMSN system could be triggered by intracellular glutathione for delivering the anticancer drug doxorubicin hydrochloride (DOX), leading to cell apoptosis in vitro. More importantly, the YMSN system displayed great potential for targeted tumor therapy in vivo, with minimal toxic side effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
